EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition

Reiko Yoshida iD, Akira Hirasawa iD, Issei Imoto, Tatsuro Yamaguchi iD, Kensuke Kumamoto, Momoko Araki, Arisa Ueki, Kenta Masuda, Yusaku Urakawa, Noriko Tanabe, Atsushi Watanabe, Makoto Hirata und 48 weitere

Cancer Science · 24.10.2026

DOI: 10.1111/cas.70566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 24.10.2026. Verfasst von Reiko Yoshida und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics and Genomics, Saitama Cancer Center, Saitama, Japan. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In March 2025, the Japanese Society for Hereditary Tumors and the Ministry of Health, Labour and Welfare (MHLW) Research on Promotion of Cancer Control Program Grant Number JPMH 23EA1037 published the “Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes with Multigene Panel Testing (MGPT), 2025 Edition.” Unlike conventional phenotype‐based guidelines, this guidance promotes preemptive cancer medicine based on genotype. The guidance establishes standardized criteria for MGPT eligibility, emphasizing its utility in both cancer‐affected and cancer‐free individuals to identify actionable germline pathogenic variants (GPVs). Key recommendations include the integration of gene‐specific curation for variant interpretation and the implementation of structured clinical practice systems for risk management. By providing evidence‐based management strategies for 56 cancer‐susceptibility genes, this guidance facilitates the shift toward genotype‐driven oncology. This digest assists healthcare providers in utilizing MGPT and supports shared decision‐making for patients and their relatives.

Schlagwörter

Stichwörter der Autor:innen

familial cancergermline pathogenic varianthereditary cancer syndromemultigene panel testingsyndrome‐specific genetic testing

Autor:innen und Institutionen

  • Department of Medical Genetics and Genomics, Saitama Cancer Center, Saitama, Japan.
  • Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Aichi Cancer Center Research Institute, Aichi, Japan.
  • Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Department of Genome Medical Science and Medical Genetics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Department of Clinical Genetics Unit, Shimane University Faculty of Medicine, Shimane, Japan.

ORCID-Profile: Reiko Yoshida, Akira Hirasawa, Tatsuro Yamaguchi, Yoshinaga Okugawa, Hirotaka Matsui, Kazuhiko Shien, Masahiko Tanabe, Hisashi Hasumi, Hiroyoshi Hattori, Hiroyuki Matsubayashi

Förderung

  • Ministry of Health, Labour and Welfare

Zitieren

APA

Yoshida, R., Hirasawa, A., Imoto, I., Yamaguchi, T., Kumamoto, K., Araki, M., Ueki, A., Masuda, K., Urakawa, Y., Tanabe, N., Watanabe, A., Hirata, M., Aruga, T., Kuwata, T., Okugawa, Y., Kaneko, K., Terui-Kohbata, H., Matsumoto, M., Ueno, S., …, & Yoshihama, T. (2026). Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition. Cancer Science. https://doi.org/10.1111/cas.70566

Vancouver

Yoshida R, Hirasawa A, Imoto I, Yamaguchi T, Kumamoto K, Araki M, et al. Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition. Cancer Science. 2026. doi:10.1111/cas.70566

BibTeX
@article{Yoshida2026,
  author = {Yoshida, Reiko and Hirasawa, Akira and Imoto, Issei and Yamaguchi, Tatsuro and Kumamoto, Kensuke and Araki, Momoko and Ueki, Arisa and Masuda, Kenta and Urakawa, Yusaku and Tanabe, Noriko and Watanabe, Atsushi and Hirata, Makoto and Aruga, Tomoyuki and Kuwata, Takeshi and Okugawa, Yoshinaga and Kaneko, Keika and Terui-Kohbata, Hiroko and Matsumoto, Megumi and Ueno, Sayaka and Oda, Katsutoshi and Ono, Hisako and Sakurai, Akihiro and Matsui, Hirotaka and Yamamoto, Gou and Yamamoto, Hideki and Yamamoto, Yasuko and Ikegami, Masachika and Ohkuma, Yusuke and Shien, Kazuhiko and Suzuki, Shigenobu and Takayanagi, Shunsaku and Tanabe, Masahiko and Hasumi, Hisashi and Hatta, Naohito and Hattori, Hiroyoshi and Matsubayashi, Hiroyuki and Yamagami, Wataru and Yamada, Masayoshi and Oishi, Kazuyuki and Oka, Tomomi and Oda, Shinya and Kobayashi, Yusuke and Takekoshi, Kazuhiro and Nakajima, Takeshi and Nakano, Yoshiko and Nakayama, Yoshiko and Miura, Fumiharu and Miyakura, Yasuyuki and Mori, Yoshiko and Yoshimura, Akiyo and Yonamine, Masato and Shigeyasu, Kunitoshi and Fujita, Hiroko and Futagawa, Mashu and Ohta, Kouji and Kawano, Junko and Tokutomi, Tomoharu and Sato, Ayaka and Makabe, Takeshi and Yoshihama, Tomoko},
  title = {Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70566}
}
Kostenlos starten →